The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 08, 2022

Filed:

Jan. 12, 2017
Applicant:

The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David Gladstone, San Francisco, CA (US);

Inventors:

Tao Xu, San Francisco, CA (US);

Sheng Ding, Orinda, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61K 31/133 (2006.01); A61K 31/42 (2006.01); A61K 31/223 (2006.01); A61K 31/195 (2006.01); A61K 31/225 (2006.01); A61K 31/197 (2006.01); A61P 37/06 (2006.01); A61P 35/00 (2006.01); A61P 29/00 (2006.01); A61K 38/20 (2006.01); A61K 38/21 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 31/133 (2013.01); A61K 31/195 (2013.01); A61K 31/197 (2013.01); A61K 31/223 (2013.01); A61K 31/225 (2013.01); A61K 31/42 (2013.01); A61P 35/00 (2018.01); A61P 37/06 (2018.01); A61K 38/20 (2013.01); A61K 38/21 (2013.01); A61P 29/00 (2018.01);
Abstract

Provided herein are methods for treating an individual for a disease (e.g., an autoimmune disease or a cancer) using an active agent which affects metabolism of α-ketoglutarate (α-KG) and/or 2-hydroxyglutarate (2-HG) in differentiating T cells. In some embodiments, a Got1 inhibitor is used to generate a population of T cells enriched in peripheral regulatory T (iTreg) cells, which population enriched in iTreg cells may find use in treating an autoimmune disease. In some embodiments, a TCA cycle-associated metabolite, or a derivative thereof, is used to generate a population of T cells in enriched in IL-17- and IL-17F-producing CD4 T (T17) cells, which population enriched in T17 cells may find use in treating a cancer.


Find Patent Forward Citations

Loading…